Yau T - Search Results

1

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.

Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, Eldawy TE, Bruix J, Frassineti GL, Vaccaro GM, Tschaika M, Scheffold C, Koopmans P, Neely J, Piscaglia F. Yau T, et al. J Clin Oncol. 2023 Mar 20;41(9):1747-1757. doi: 10.1200/JCO.22.00972. Epub 2022 Dec 13. J Clin Oncol. 2023. PMID: 36512738 Free PMC article. Clinical Trial.

2

Evolution of systemic therapy for advanced HCC patients: Did we make progress in 2022?

Wong JSL, Leung R, Cheung TT, Yau T. Wong JSL, et al. Among authors: yau t. Hepatol Commun. 2023 May 15;7(6):e0117. doi: 10.1097/HC9.0000000000000117. eCollection 2023 Jun 1. Hepatol Commun. 2023. PMID: 37184515 Free PMC article. No abstract available.

3

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong-A Territory-Wide Cohort Study.

Wong JS, Dong Y, Tang V, Leung T, Yeung CSY, Tai A, Law A, Shum T, Kwok GG, Li BC, Leung R, Chiu J, Ma KW, She WH, Tsang J, Cheung TT, Yau T. Wong JS, et al. Among authors: yau t. Cancers (Basel). 2021 Apr 21;13(9):2002. doi: 10.3390/cancers13092002. Cancers (Basel). 2021. PMID: 33919277 Free PMC article.

4

A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients.

Yau T, Cheng PNM, Chiu J, Kwok GGW, Leung R, Liu AM, Cheung TT, Ng CT. Yau T, et al. Invest New Drugs. 2022 Apr;40(2):314-321. doi: 10.1007/s10637-021-01178-3. Epub 2021 Nov 4. Invest New Drugs. 2022. PMID: 34735674 Clinical Trial.

5

The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.

Chow AK, Ng L, Lam CS, Wong SK, Wan TM, Cheng NS, Yau TC, Poon RT, Pang RW. Chow AK, et al. PLoS One. 2013 Nov 11;8(11):e78675. doi: 10.1371/journal.pone.0078675. eCollection 2013. PLoS One. 2013. PMID: 24244338 Free PMC article.

6

CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.

Chan CY, Chiu DK, Yuen VW, Law CT, Wong BP, Thu KL, Cescon DW, Soria-Bretones I, Cheu JW, Lee D, Tse AP, Zhang MS, Tan KV, Ng IO, Khong PL, Yau TC, Bray MR, Mak TW, Wong CC. Chan CY, et al. Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2119514119. doi: 10.1073/pnas.2119514119. Epub 2022 Aug 1. Proc Natl Acad Sci U S A. 2022. PMID: 35914158 Free PMC article.

7

Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.

Koh B, Tan DJH, Lim WH, Wong JSL, Ng CH, Chan KE, Wang M, Yong WP, Dan YY, Wang LZ, Tan N, Muthiah M, Kow A, Syn NL, Huang DQ, Yau T. Koh B, et al. Among authors: yau t. Oncoimmunology. 2023 Jun 3;12(1):2214478. doi: 10.1080/2162402X.2023.2214478. eCollection 2023. Oncoimmunology. 2023. PMID: 37284696 Free PMC article. Review.

8

Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.

Chiu DK, Yuen VW, Cheu JW, Wei LL, Ting V, Fehlings M, Sumatoh H, Nardin A, Newell EW, Ng IO, Yau TC, Wong CM, Wong CC. Chiu DK, et al. Gastroenterology. 2020 Aug;159(2):609-623. doi: 10.1053/j.gastro.2020.03.074. Epub 2020 Apr 8. Gastroenterology. 2020. PMID: 32275969

9

Malignancies in spondyloarthritis with and without concomitant psoriasis, and the effect of disease modifying anti-rheumatic drugs.

Chung HY, Chan SCW, Chui ETF, Yau T, Lau CS. Chung HY, et al. Among authors: yau t. Clin Exp Rheumatol. 2022 May;40(5):913-920. doi: 10.55563/clinexprheumatol/o3rgv1. Epub 2021 Jul 24. Clin Exp Rheumatol. 2022. PMID: 34369368

10

Correction: Days alive and out of hospital for adult female and male cardiac surgery patients: a population-based cohort study.

Jerath A, Wallis CJD, Fremes S, Rao V, Yau TM, Heybati K, Lee DS, Wijeysundera HC, Sutherland J, Austin PC, Wijeysundera DN, Ko DT. Jerath A, et al. Among authors: yau tm. BMC Cardiovasc Disord. 2024 May 24;24(1):274. doi: 10.1186/s12872-024-03944-6. BMC Cardiovasc Disord. 2024. PMID: 38789938 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

584 results

Search Page